Price
$0.83
Increased by 0.00%
Dollar Volume
548.09 K
ADR%
9.23
Earnings Report Date (estimate)
Feb 27, 23 (-0.06)
Market Cap.
105.10 M
Shares Float
118.83 M
Shares Outstanding
126.62 M
Beta
1.13
Price / Earnings
-4.77
BPR
30.51
20D Range
0.66 1.00
50D Range
0.50 1.00
200D Range
0.50 1.36
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 22 -0.06
Decreased by -50.00%
-0.06
Aug 8, 22 -0.05
Increased by +16.67%
-0.06
Increased by +16.67%
May 9, 22 -0.04
Increased by 0.00%
-0.05
Increased by +20.00%
Feb 28, 22 -0.04
Increased by +95.45%
-0.04
Nov 15, 21 -0.04
Increased by +88.24%
-0.04
Aug 13, 21 -0.06
Increased by +86.05%
-0.04
Decreased by -50.00%
May 14, 21 -0.04
Increased by +87.50%
-0.05
Increased by +20.00%
Mar 31, 21 -0.88
Decreased by -238.46%
-0.27
Decreased by -225.93%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-8.01 M
Decreased by -54.14%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-6.67 M
Increased by +5.22%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-4.79 M
Decreased by -35.27%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-4.83 M
Increased by +72.90%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-5.20 M
Decreased by -48.87%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by N/A%
-7.04 M
Decreased by -80.21%
Decreased by N/A%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-3.54 M
Decreased by -20.04%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-17.83 M
Decreased by -580.97%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.